Dr. Anan Jongkaewwattana, Head of BIOTEC Virology and Cell Technology Laboratory, and his team have successfully generated seed vaccines using genetic materials of the novel human influenza virus, A/Nonthaburi/102/2009 (H1N1), isolated from the country's first confirmed patient. The seed viruses are generated based on the genetic constellation of the first candidate vaccine, so-called NYMC-179A, announced by US-CDC in May. Instead of using classical egg-based selection method, Anan has employed reverse genetics technology to construct a "5+3" reassortant virus that can grow efficiently in embryonated chicken eggs. The seed virus has also been developed, also by reverse genetics, as live-attenuated vaccine by Dr. Prasert Auewarakul and Dr. Onpreeya Saptaveewat of Siriraj Hospital.
Both seed vaccines will be tested for the safety and immunogenicity in ferrets, which can take from 2-3 months before they can be mass produced.
Dr. Anan Jongkaewwattana (center) with his team at BIOTEC Virology and Cell Technology Laboratory
Posted on 14 July 2009.